PALMISANO ROBERT J 4

What Happened
Robert J. Palmisano, a director of AEON Biopharma, was granted 222,684 restricted stock units (RSUs) on June 17, 2026. The reported acquisition price was $0.00 (standard for RSU grants), so the Form 4 records a $0 total for the transaction. This is a compensation award rather than an open-market purchase or sale.

Key Details

• Transaction date: June 17, 2026; Filing date: June 22, 2026 (filed 5 days after the transaction). This appears later than the typical 2-business-day Form 4 deadline.
• Transaction type/code: A = Award/Grant of RSUs. Reported price: $0.00. Shares acquired: 222,684 RSUs. Reported dollar amount: $0.
• Vesting: RSUs vest in full on the earlier of (i) one-year anniversary of the grant (June 17, 2027) or (ii) the date of the 2027 annual meeting of stockholders, subject to continued service. (Footnote from the filing.)
• Shares owned after transaction: Not specified in the disclosed Form 4.
• No indication of a 10b5-1 plan, tax withholding sale, or cashless exercise in this filing.

Context
RSU grants are a common form of equity compensation for directors and executives; they do not represent an immediate purchase or sale and typically require continued service to vest. Because this is an award (not a purchase), it should be interpreted as compensation-related rather than a direct bullish or bearish trading signal. The late filing may be a compliance issue to monitor but does not change the nature of the award.